Meet our directors
Jeffrey Meyerhardt, MD, MPH, is a leading expert in colorectal cancer and has conducted both clinical trial research to find more efficacious therapies for treating colon and rectal cancer as well
as research on diet and lifestyle in colorectal cancer survivors. He is the Co-Chair of one of the National Cancer Institute cooperative groups' committees (Alliance) focused on gastrointestinal cancers. He has served on national committees to develop
guidelines for the treatment of colon and rectal cancers, including the American Society of Clinical Oncology and the American Cancer Society.
Ronald Bleday, MD, is chief of colon and rectal surgery at Brigham and Women's Hospital (BWH). Dr. Bleday has been the principal investigator or contributor to various clinical trials on the use of
local excision for the treatment of early rectal cancer and the use of laparoscopy versus open surgery for the treatment of colon cancer. He is collaborating with scientists at Harvard Medical School looking into the basic molecular mechanisms of
colon cancer biology and immunology. He has also implemented new protocols for "Enhanced Recovery after Surgery" or "ERAS" and infection reduction for gastrointestinal surgery patients at BWH. He serves on the board of the Research Foundation of the
American Society of Colon and Rectal Surgery.
At the Colon and Rectal Cancer Center of Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), our specialists are dedicated to making discoveries in every discipline.
Our medical oncologists are improving the use of chemotherapy and targeted agents through clinical trials and new treatment approaches, such as with
precision cancer medicine based on genetic testing.
Our surgeons use the newest approaches, including sphincter-saving surgery for rectal cancer patients, robotic surgery, and minimally-invasive surgery.
Our radiologists are pioneering the use of imaging tests to allow optimal diagnosis and treatment of patients with colon and rectal cancer.
Our interventional radiologists use the latest techniques including radioembolization and radiofrequency ablation. They hold a weekly conference to evaluate patients with liver metastases to determine the best treatment options.
Our genetic risk experts are identifying biochemical markers of gastrointestinal cancer risk and are researching novel targets for therapy. They have deep expertise in
cancer genetics and prevention.
Our pathologists work closely with our
Center for Molecular Diagnostics to get a complete picture of a tumor in order to direct the
Our radiation oncologists are discovering better combinations of radiation and systemic therapies, and have identified biomarkers for the response to treatment.
Our gastroenterologists are using innovative
advanced endoscopic techniques to evaluate tumors. We have expertise in removing early-stage
lesions with endoscopy.
Our scientists are working to understand the fundamental biology of these cancers to identify new ways to prevent and treat these diseases in our patients.
Our support teams offer a range of programs to individuals and families, including social work, nutritional counseling, palliative care, integrative therapies, and support groups.
Our nurses, including nurse practitioners and infusion nurses, are certified and trained in oncology nursing and set new standards in caring for patients with gastrointestinal cancers.
See an entire list of our
gastrointestinal cancer specialists.